Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

In vitro diagnostic models for ALL: what can we learn on actionable targets?

ALL Assembly 2018

Published: 18 Oct 2018

Views: 2400

Rating:

Save

Dr Beat Bornhauser - Senior Scientist, University of Zurich, Zurich, Switzerland

Dr Beat Bornhauser talks to ecancer at the ALL Assembly 2018 Meeting in Amsterdam about in vitro diagnostic models for ALL and what we can learn on actionable targets.

Dr Bornhauser explains that a co-cultured system can be used where primary leukaemia cells are cultured on top of mesenchymal stroma cell.

He states that library of agents is expanding all the time and that he would like to look at the correlation of activity of agents with effects on the platform.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related Videos

Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results

Prof Stefano Luminari - University of Modena and Reggio Emilia, Modena, Italy

Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results ( Prof Stefano Luminari - University of Modena and Reggio Emilia, Modena, Italy )

Physics of hypofractionated radiotherapy

Dr Nataliya Kovalchuk - Stanford University, Stanford, USA

$Physics of hypofractionated radiotherapy ( Dr Nataliya Kovalchuk - Stanford University, Stanford, USA )$

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM

Dr Jill Corre - IUCT Oncopole, Toulouse, France

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM ( Dr Jill Corre - IUCT Oncopole, Toulouse, France )

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Guiding transplant decisions in multiple myeloma with MRD

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Guiding transplant decisions in multiple myeloma with MRD ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

Predicting tumour mutations from pathology images may help increase personalised medicine utilisation

Dr Rom Leidner - Providence Cancer Institute, Portland, USA

Predicting tumour mutations from pathology images may help increase personalised medicine utilisation ( Dr Rom Leidner - Providence Cancer Institute, Portland, USA )

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

More from ecancer